WHAT IS CLAIMED IS:

1. A peptide or a salt thereof, said peptide having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof.

2. The peptide according to claim 1 or a salt thereof, wherein each of the 4 glutamine-derived amino acid residues is glutamine, and the peptide is a depsipeptide having a cyclic structure therein.

3. The peptide according to claim 2 or a salt thereof, wherein the peptide has the following formula (I):



(I)

4. The peptide according to claim 1 or a salt thereof, wherein each of the 4 glutamine-derived amino acid residues is α,γ-diaminobutyric acid, and the peptide is a depsipeptide having a cyclic structure therein.

5. The peptide according to claim 4 or a salt thereof wherein the peptide has the following formula (II):



(II)

6. The peptide according to claim 1 or a salt thereof, wherein each of the 4 glutamine-derived amino acid residues is α,γ-diaminobutyric acid, and the peptide is a linear peptide.

7. The peptide according to claim 6 or a salt thereof, wherein the peptide has the following formula (III):



(III)

8. A lower-alkylated derivative of the peptide according to claim 3 or a salt thereof.

9. The lower-alkylated derivative according to

claim 8 or a salt thereof, wherein said derivative having the following formula (VI):



(VI)

wherein R represents a lower alkyl group.

10. The lower-alkylated derivative according to claim 9, wherein R is a methyl group or a salt thereof.

11. A peptide or a salt thereof, wherein said peptide having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof.

12. The peptide according to claim 11 or a salt thereof, wherein each of the 4 glutamine-derived amino acid residues is glutamine, and the peptide is a depsipeptide having a cyclic structure therein.

13. The peptide according to claim 12 or a salt thereof, wherein the peptide has the following formula (IV):



(IV)

14. A peptide or a salt thereof, wherein said peptide having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue, and 5 leucine residues, and having a 3-hydroxydodec-5-enoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof.

15. The peptide according to claim 14 or a salt thereof, wherein each of the 4 glutamine-derived amino acid residues is glutamine, and the peptide is a depsipeptide having a cyclic structure therein.

16. The peptide according to claim 15 or a salt thereof, wherein the peptide has the following formula (V):



(V)

17. A method of preparing at least one peptide selected from the group consisting of:

(i) peptides having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof;

(ii) peptides having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof; and

(iii) peptides having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue, and 5 leucine residues, and having a 3-hydroxydodec-5-enoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue

thereof,

comprising:

culturing at least one strain capable of producing at least one peptide selected from the peptides (i) to (iii) mentioned above; and

recovering, from the culture product, at least one peptide selected from the peptides (i) to (iii) mentioned above.

18. A strain belonging to genus *Pseudomonas*, wherein the strain is capable of producing any one of peptides selected from the group consisting of:

(i) peptides having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof;

(ii) peptides having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof; and

(iii) peptides having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue, and 5 leucine residues, and

having a 3-hydroxydodec-5-enoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof.

19. The strain according to claim 18, wherein the strain belongs to a novel species.

20. The strain according to claim 18, wherein the strain is *Pseudomonas* sp. RtIB026.

21. The strain according to claim 18, wherein the strain is *Pseudomonas* sp. RtIB026 deposited under accession number FERM BP- 7436.

22. An antiviral agent comprising, as an effective ingredient, at least one component selected from the group consisting of (a) and (b):

(a) at least one peptide selected from the group consisting of (i) to (v) below:

(i) peptides having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof;

(ii) peptides having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group that is bonded, via an

amide linkage, to the N-terminal leucine residue thereof;

(iii) peptides having, as constitutive amino acids, 4 glutamine-derived amino acid residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue, and 5 leucine residues, and having a 3-hydroxydodec-5-enoyl group that is bonded, via an amide linkage, to the N-terminal leucine residue thereof;

(iv) derivatives of (i) mentioned above; and

(v) pharmaceutically acceptable salts of (i) to (iv) mentioned above; and

(b) at least one strain selected from the group consisting of the strains capable of producing any one of the peptides (i) to (iii) mentioned above.

23. A method of preventing and treating a subject infected with a virus, wherein the method comprises administering to the subject in need thereof the antiviral agent according to claim 22.